Globe Catheter and Globe Pulsed Field System
Kardium, Inc. · Decision date Jun 23, 2026
What did the FDA approve?
FDA records P240044/S001 as a supplement to PMA P240044, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 23, 2026.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240044
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 23, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240044/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Kardium, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Jun 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Kardium, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240044 · Original PMA
Globe Pulsed Field System
P240044/S001 received
Application receipt date recorded by FDA.
P240044/S003 · Related supplement
Globe Pulsed Field System
P240044/S004 · Related supplement
Globe Catheter; Globe Pulsed Field System
P240044/S002 · Related supplement
Globe Catheter (601-01000)
P240044/S005 · Related supplement
Globe Catheter; Globe Pulsed Field System
P240044/S001 · FDA decision
Normal 180 Day Track No User Fee
P240044/S006 · Related supplement
Globe Catheter Laminated Ribs
P240044/S008 · Related supplement
Globe Pulsed Field System; Globe Catheter
P240044/S007 · Related supplement
Globe Catheter and Globe Pulsed Field System
Timeline entries are records held by MedtechLedger for P240044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Globe Pulsed Field SystemP240044 | Kardium, Inc. | PMA approval | Aug 27, 2025 | FDA |
Globe Pulsed Field SystemP240044/S003 | Kardium, Inc. | PMA supplement | Jan 6, 2026 | FDA |
Globe Catheter; Globe Pulsed Field SystemP240044/S004 | Kardium, Inc. | PMA supplement | Jan 9, 2026 | FDA |
Globe Catheter (601-01000)P240044/S002 | Kardium, Inc. | PMA supplement | Feb 18, 2026 | FDA |
Globe Catheter; Globe Pulsed Field SystemP240044/S005 | Kardium, Inc. | PMA supplement | Jun 12, 2026 | FDA |
Globe Catheter Laminated RibsP240044/S006 | Kardium, Inc. | PMA supplement | Aug 20, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
VOLT PFA CATHETER, SENSOR ENABLEDP250022/S012 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kardium, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6
Sources and methodology
- Original FDA record: P240044/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


